United States Ebola Vaccine Market Insights | Key Players, Regulatory Updates & Market Scope

Ebola Virus Vaccine Market reached US$173.82 million in 2024 and is expected to reach US$288.41 million by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033, according to DataM intelligence research.

According to DataM Intelligence has released its latest research report on "Ebola Virus Vaccine Market Size 2025," offering in-depth insights into key growth factors such as regional performance, market segmentation, CAGR trends, revenue analysis of leading players, and major drivers shaping the industry. This report provides a clear and forward-looking perspective on market size (both value and volume), emerging opportunities, and current development status helping businesses identify growth potential and make informed strategic decisions

According to WHO data from August 2023, two monoclonal antibody treatments mAb114 (Ansuvimab; Ebanga) and REGN-EB3 (Inmazeb) are strongly recommended for Ebola due to their proven effectiveness. Ebola's fatality rate averages around 50%, though it has varied between 25% and 90% in past outbreaks depending on conditions and response efforts.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/ebola-virus-vaccine-market?kb

In July 2024, the Sabin Vaccine Institute began a Phase 2 clinical trial in Uganda for its single-dose Sudan ebolavirus vaccine, which currently has no approved alternatives. The trial is being conducted with healthy volunteers at the Makerere University Walter Reed Project (MUWRP).

Zaire ebolavirus, the deadliest of the five Ebola virus species, is responsible for most global outbreaks. It causes hemorrhagic fever in humans and non-human primates, with fatality rates often exceeding 50%. First detected during the 1976 Ebola outbreak in Zaire, the virus was named after the region.

North America is home to major pharmaceutical companies and research institutions, including Merck & Co., Johnson & Johnson, and Moderna, which are at the forefront of Ebola vaccine development. They have introduced vaccines like Ervebo (V920) and continue to work on new formulations targeting multiple Ebola strains and combination vaccines.

In May 2024, RedHill Biopharma secured a new Chinese patent for opaganib as a treatment to inhibit single-stranded RNA virus replication, including Ebola. This patent, valid until 2035, enhances the company's intellectual property portfolio.

In August 2023, the U.S. FDA expanded the approval of Merck's ERVEBO vaccine to include children as young as 12 months, allowing its use for preventing Zaire ebolavirus in individuals aged 12 months and older. Previously, it was limited to those 18 and above.

Top Key Players:

Johnson & Johnson, Merck & Co., Inc., GSK plc., CansinoBl0, and AIM ImmunoTech Inc. among others.

Growth Projection:

The Global Ebola Virus Vaccine Market is set to witness significant growth between 2025 and 2032. While 2024 reflects steady progress, the increasing adoption of innovative strategies by leading players is expected to accelerate growth across the projected horizon. This creates a strong landscape of opportunities for businesses looking to expand, invest, and stay competitive in a rapidly evolving market.

Research Process:

The Ebola Virus Vaccine Market research report by DataM Intelligence leverages both primary and secondary data sources to deliver deep insights. It explores a wide range of factors shaping the industry from government regulations, market conditions, and competitive dynamics to historical trends, technological advancements, upcoming innovations, and potential challenges. This comprehensive analysis highlights growth prospects while addressing barriers, helping businesses navigate volatility and seize new opportunities

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ebola-virus-vaccine-market

Market Segmentation:

By Strain Type: Zaire Ebolavirus | Sudan Virus | Taï Forest Virus | Others

By Vaccine Type: rVSV-ZEBOV | Ad26.ZEBOV and MVA-BN-Filo | Others

By End-User: Hospitals | Specialized Clinics | Others

Top Growth Regions:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Introduces the report with an overview of coverage summarizing key market segments by region, product type, and application. It offers a clear snapshot of market size, segment-wise growth potential, and both short- and long-term industry outlook.

Chapter 2: Brings forward the most valuable market insights and reveals the game-changing emerging trends shaping the industry's future.

Chapter 3: Provides a detailed analysis of the competitive landscape among Ebola Virus Vaccine covering revenue shares, strategic initiatives, and the latest mergers & acquisitions.

Chapter 4: Delivers comprehensive profiles of top players, including revenue, profit margins, product lines, and company milestones.

Chapters 5 & 6: Break down revenue performance across regions and countries, offering a precise view of market sizes, opportunities, and development prospects worldwide.

Chapter 7: Examines segmentation by type, revealing the size and potential of each category guiding businesses toward untapped, high-impact areas.

Chapter 8: Focuses on applications, evaluating how different downstream markets are growing and identifying promising sectors for expansion.

Chapter 9: Maps the entire industry supply chain, detailing both upstream and downstream activities for a holistic understanding.

Chapter 10: Concludes with key findings and the most critical takeaways giving stakeholders a clear direction for future strategies.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/ebola-virus-vaccine-market?kb

Q1: How fast is the Ebola Virus Vaccine Market growing?

A: The Market is on a robust growth path, expected to expand at a CAGR of 6.4% between 2025 and 2032.

Q2: Which Regions dominate the Ebola Virus Vaccine Market?

A: North America is projected to hold a major share of the global Ebola virus vaccine market.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.